Legend Biotech Corporation announced preliminary business results for the quarter ended December 31, 2025. According to information provided by Janssen, CARVYKTI® generated approximately $555 million in net trade sales during the quarter. The sales figure is based on data available to Legend Biotech as of the date of the announcement and has not been independently verified by the company. The determination of revenue or gross profit to be recorded in Legend Biotech's consolidated financial statements is subject to completion by management and review by independent auditors. The company noted that actual results may differ materially from forward-looking statements due to various factors, including regulatory actions, clinical trial outcomes, and market competition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-000356), on January 21, 2026, and is solely responsible for the information contained therein.